Cytokine Release Syndrome

The "Cytokine Release " course  is 1 of 10 courses included in the Cancer Immunotherapies Module  and is led by Dr. Madeline Fort, PhD- at  Amgen

Learning Objectives

Cytokine Release Syndrome:  CRS is a common toxicity in T cell-targeting immunotherapies for cancer.  CRS can cause serious adverse events in patients and therefore understanding the risks and mitigation is a key area of investigation. 

1. We will review the definition of CRS, its clinical manifestations, and current clinical approaches for CRS mitigation. 

2. We will also review the current science behind the cytokine release observed with CD3-targeting bispecific therapies, the challenges for translation from nonclinical cytokine release to patient risk, and potential new approaches for CRS risk mitigation.   

Course summary
Course opens: 
03/22/2022
Course expires: 
03/23/2027
Cost:
$25.00
Rating: 
0

Price

Cost:
$25.00
Please login or register to take this course.